NY-WOVEN-PLANET-HOLDINGS
14.7.2021 23:02:10 CEST | Business Wire | Press release
Woven Planet Holdings, Inc. (“Woven Planet”), a subsidiary of the Toyota Motor Corporation, announced the acquisition of CARMERA, Inc. (“CARMERA”), a U.S.-based spatial AI company, which specializes in bringing next-generation road intelligence to automated mobility at scale. This is the second major deal for Woven Planet in North America, following the April 2021 announcement to acquire Level 5, the self-driving division of Lyft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210714005892/en/
Once the deal is closed, the CARMERA team will report into the Automated Mapping Platform (“AMP”) organization of Woven Alpha, Inc. (“Woven Alpha”). Woven Alpha focuses on exploring new strategic areas for business expansion and incubates several innovative projects such as Woven City and Arene, which is Woven Planet’s open software platform. AMP is a connected crowdsourced software platform that supports the creation, development and distribution of high definition (“HD”) maps—a key enabler for smart and safe automated mobility.
The Woven Alpha team plans to develop AMP to become the most globally comprehensive road and lane network HD map platform, enabling high-precision localization support to automated vehicles. The acquisition of CARMERA will accelerate AMP’s shift from the R&D stage to the next phase of commercialization by bolstering the platform’s engineering team with top experts in the development of HD maps. In addition, it will provide access to CARMERA’s sophisticated map update, change management and IoT sensing technology.
Together, the teams will tap into CARMERA’s ability to successfully update HD maps from crowdsourced, camera-based inputs—a significantly cheaper and faster approach than traditional methods. This will strengthen AMP’s ability to serve a comprehensive set of road classes and features, reflecting changes in lane markings, traffic signals, signs and more in near real-time, and support its future multi-regional commercial launch.
CARMERA will join Woven Planet Group as a wholly-owned subsidiary, expanding the company’s footprint beyond its Tokyo headquarters by adding New York and Seattle offices to its planned offices in Silicon Valley and London.
Comment from Mandali Khalesi, Vice President of Automated Driving Strategy and Mapping, Woven Planet:
“AMP has been a key project of Woven Planet since its foundation, helping support its vision of ‘Mobility to Love, Safety to Live.’ We’ve been progressing steadily in bringing safe automated mobility to the passenger and commercial vehicle segments, such as our recent announcements with Isuzu Motors Limited and Hino Motors, Ltd., and with Mitsubishi Fuso Truck and Bus Corporation. I’m really excited to welcome CARMERA to Woven Planet. With CARMERA joining the team, we’ll be able to hit the accelerator. CARMERA’s software stack, which is focused on real-time HD map changes and proprietary hardware custom-tailored to crowdsourcing, is an ideal complement to AMP’s mapping efforts. In addition, their world-class experts will allow us to bring forward the execution of key strategic milestones and jumpstart operations in the United States.”
Comment from Ro Gupta, CEO and Co-founder, CARMERA:
“Woven Planet and AMP have been highly aligned with CARMERA’s culture and mission from the beginning. Our teams have a common view of the unmet need for ubiquity in advanced mobility data going forward, including maps. Woven Planet, thanks to its software-first automotive DNA, shares our commitment to the end-user—to creating a technology stack that can be used safely and without friction by all stakeholders from data originators through to data consumers. This validates and furthers our founding thesis that richer, faster spatial intelligence is both critical to the next generation of ‘Mobility for All’ and viable at global-production scale. I’m beyond excited for CARMERA to join the Woven Planet organization, as it continues to strengthen its footprint in North America and ramp up its software-first development of mobility innovations.”
An earlier partnership between Woven Planet—under its predecessor organization Toyota Research institute - Advanced Development, Inc.—and CARMERA in Tokyo, Detroit and Ann Arbor, Michigan, laid the groundwork for this deal. Woven Planet and CARMERA participated in collaborative projects in 2018, 2019 and 2020, which proved the companies can successfully develop and update HD maps from commodity, device-agnostic sources, such as commercially available dashboard-mounted cameras.
About Woven Planet Group
Woven Planet Group represents a carefully curated blend of expertise and resources dedicated to bringing the vision of “Mobility to Love, Safety to Live” to life. Through innovations and investments in automated driving, robotics, smart cities, and more, we are transforming how humankind lives, works, and moves. We exist to design, build, and deliver secure, connected, and sustainable mobility solutions that benefit all people worldwide. Founded in 2018 as Toyota Research Institute - Advanced Development (TRI-AD), Woven Planet Group is composed of four complementary companies: Woven Planet Holdings, Woven Core, Woven Alpha, and Woven Capital.
For more information, please visit: https://www.woven-planet.global/
About CARMERA
CARMERA is a spatial AI company, built on the revolution of vehicular crowdsourcing and remote sensing to capture street-level change, at global breadth and high definition depth. CARMERA employs an open systems approach to working with the world’s leading automotive companies, commercial mobility operators, and mapping platforms. With a team hailing from leading geospatial, machine learning and computer vision organizations, and venture backing from GV (Google Ventures) among others, the company is headquartered in New York City and Seattle. CARMERA is the recipient of multiple industry awards, including Frost & Sullivan’s 2020 North American Mapping Company of the Year.
For more information, please visit: https://www.carmera.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005892/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom